Braidwell LP is a venture capital firm that primarily focuses on later-stage investments within the healthcare and life sciences sectors, including biotechnology, pharmaceuticals, medical devices, and diagnostics. Their strategy involves a fundamental, research-driven approach, providing flexible capital and partnership to companies aiming to advance human health.
86% of their portfolio is in Biotech & Life Sciences. Their most common stage is growth (43% of deals). Average disclosed round size is $181.8M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$3.1B
Top Stage
Growth
Last 12 Mo
2
Team
IS
Ilan Sender
Principal – Public Equities
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Surrozen, Inc. | Series D | $175M | Mar 2025 |
| PPerceive Pharma | Series A | $15M | Feb 2025 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Caris Life Sciences | Growth | $400M | Jan 2023 |
 Jade Biosciences | Series C | $95M | — |
| OOruka Therapeutics | Growth | $275M | — |
Top Co-Investors
Deep Track Capital4 shared
RTW Investments3 shared
Frazier Life Sciences2 shared
Access Biotechnology2 shared
RA Capital Management2 shared
Samsara BioCapital2 shared
Fairmount2 shared
Commodore Capital2 shared
Perceptive Advisors2 shared
BVF Partners LP2 shared
Logos Capital2 shared
Paradigm BioCapital2 shared
GV (Google Ventures)1 shared
Deerfield1 shared
Retinal Degeneration Fund1 shared
Versant Ventures1 shared
Franklin Templeton1 shared
The Column Group1 shared
Vivo Capital1 shared
Last updated: 8 March 2026